ARTICLE | Clinical News
Halaven eribulin mesylate regulatory update
April 25, 2016 7:00 AM UTC
EMA’s CHMP recommended expanding the label of Eisai’s Halaven eribulin to include treatment of unresectable liposarcoma in adults who have received prior anthracycline-containing therapy for advanced ...